M.L.D. receives consulting fees from Bristol Myers Squibb, Kite/Gilead, Synthekine, A2 Biotherapeutics and Adicet. M.L.D. has equity or options with Adicet, A2 Biotherapeutics and Adaptive Biotechnologies. H.H. declares no competing interests.